Estrogen treatment improves arterial distensibility, fibrinolysis, and metabolic profile in postmenopausal women with type 2 diabetes mellitus
| Autor: | Claudia, Sztejnsznajd, Maria Elizabeth Rossi, Silva, Maria Elizabeth Rossi, da Silva, Amit, Nussbacher, Otavio Eluf, Gebara, Elbio Antônio, D'Amico, Dalva Marriero, Rocha, Tania Rubia Flores, da Rocha, Rosa Ferreira, Santos, Rosa Ferreira, dos Santos, Maurício, Wajngarten, Rosa Tesumechiro, Fukui, Márcia Regina Soares, Correia, Bernardo Leo, Wajchenberg, Mileni Josefina Maria, Ursich |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism medicine.medical_treatment Type 2 diabetes Placebo chemistry.chemical_compound Endocrinology Internal medicine Plasminogen Activator Inhibitor 1 Fibrinolysis medicine Humans Pulse wave velocity Glycemic Estrogens Conjugated (USP) Factor VIII Triglyceride business.industry Arteries Glucose Tolerance Test Middle Aged medicine.disease Postmenopause Cholesterol Diabetes Mellitus Type 2 chemistry Glycated hemoglobin business Body mass index |
| Zdroj: | Metabolism. 55:953-959 |
| ISSN: | 0026-0495 |
| Popis: | The effects of isolated estrogen therapy on the hemostatic system and arterial distensibility were determined in postmenopausal females with type 2 diabetes mellitus. This was a prospective nonrandomized study of 19 subjects (age, 56.2 +/- 4.7 years; body mass index, 27.8 +/- 2.4 kg/m(2) [mean +/- SD]). Inclusion was done after 2 months of glycemic and blood pressure control. The study consisted of 4 months of placebo treatment immediately followed by an equal period of oral conjugated equine estrogens (CEE) 0.625 mg/d. Measures included anthropometrics, a metabolic profile (oral glucose tolerance test and fasting glycated hemoglobin, total cholesterol and fractions, and triglyceride levels), and coagulation and fibrinolytic factors at the end of the placebo period and after 4 months of oral CEE. Conjugated equine estrogen therapy decreased plasminogen activator inhibitor 1 (placebo x CEE: 16.33 +/- 9.11 x 13.08 +/- 8.87 UI/mL, P.03) and increased factor VIII activity (134.11% +/- 46.18% x 145.33% +/- 42.04%, P.04). An increase in high-density lipoprotein cholesterol levels (placebo x CEE: 42.47 +/- 6.80 x 53.32 +/- 11.89 mg/dL, P.01), and a decrease in glycated hemoglobin (8.45% +/- 1.30% vs 7.58% +/- 1.06%, P.02) and in fasting glucose levels (121.51 +/- 21.05 x 111.21 +/- 20.74 mg/dL, P = .02) followed CEE therapy. Pulse wave velocity and augmentation index were performed by applanation tonometry and were obtained at the end of the placebo period (placebo), again after an intravenous load of 1.25 mg of CEE (short-term), and after 4 months of oral CEE (long-term). A significant decrease in central (carotid-femoral) pulse wave velocity was seen both after short- and long-term CEE (placebo vs short-term vs long-term: 9.36 +/- 2.58 vs 8.26 +/- 2.20 vs 7.98 +/- 1.90 m/s, respectively [analysis of variance, P.03]; placebo vs short-term, P.05; placebo vs long-term, P.01), whereas augmentation index decreased only after long-term CEE (placebo vs short-term vs long-term: 39.14% +/- 6.94% vs 37.48% +/- 8.67% vs 34.3.3% +/- 8.11% [analysis of variance, P.05], respectively; placebo vs long-term, P.05). Long-term administration of CEE leads to an improvement in fibrinolysis and arterial distensibility, associated with an increase of the intrinsic coagulation pathway in postmenopausal women with type 2 diabetes mellitus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect